Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland

Harvima, Rauno J.; Gooderham, Melinda; Tyring, Stephen K.; Thoning, Henrik; Nyholm, Nanna; Gold, Linda F Stein

doi:10.1080/09546634.2021.1942419

Cited by 3 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Patients on proactive treatment were estimated to have more than twice the odds of achieving response on mPASI 75, mPASI 90 and mPASI ≤1, and statistically significantly higher odds ratio for mPASI ≤2 and DLQ1 ≤1 compared to reactive treatment patients. 15 The proactive management was also associated with significant improvements in DLQI and patient-perceived symptom severity over conventional reactive treatment. 16 At the same time, the safety profile was assessed as favorable, with no observed complications in the form of skin atrophy, or a clinically significant effect on the hypothalamus-pituitary-adrenal axis, or calcium metabolism.…”

Section: Medications Used In Long-term Topical Therapy Of Psoriasismentioning

confidence: 92%

“…Moreover, the study revealed that mean BSA remained at lower levels in patients on proactive management compared to reactive management 14 . Patients on proactive treatment were estimated to have more than twice the odds of achieving response on mPASI 75, mPASI 90 and mPASI ≤1, and statistically significantly higher odds ratio for mPASI ≤2 and DLQ1 ≤1 compared to reactive treatment patients 15 . The proactive management was also associated with significant improvements in DLQI and patient‐perceived symptom severity over conventional reactive treatment 16 .…”

Section: Proactive Topical Therapymentioning

confidence: 99%

“…5 The analysis of the PSO-LONG study exploring the cost benefits of proactive versus reactive management with Cal/BD foam for the treatment of plaque psoriasis in Finland found a markedly lower cost-per-responder for the response criteria of mPASI 75, mPASI ≤2 and DLQ1 ≤1. 15 From the patient's perspective, proactive management was associated with minimally higher annual drug cost (€685) due to more treatment days during the maintenance phase compared to reactive management (€639). 15 Nevertheless, proactive treatment may increase adherence, as standard and simple schedules of treatment are more efficient than schedules based on the "on demand" use.…”

Section: Medications Used In Long-term Topical Therapy Of Psoriasismentioning

confidence: 99%

“…Thus, the PSO‐LONG study provided evidence that the use of Cal/BD in foam in the proactive versus reactive therapy ensures a better long‐term control of psoriasis with the assumed safety maintained 5 . The analysis of the PSO‐LONG study exploring the cost benefits of proactive versus reactive management with Cal/BD foam for the treatment of plaque psoriasis in Finland found a markedly lower cost‐per‐responder for the response criteria of mPASI 75, mPASI ≤2 and DLQ1 ≤1 15 . From the patient's perspective, proactive management was associated with minimally higher annual drug cost (€685) due to more treatment days during the maintenance phase compared to reactive management (€639) 15 .…”

Section: Proactive Topical Therapymentioning

confidence: 99%

See 3 more Smart Citations

Proactive therapy: New perspectives for long‐term topical treatment of psoriasis

Lis‐Święty

Frątczak

2022

Dermatologic Therapy

View full text Add to dashboard Cite

Mild to moderate psoriasis is most often treated with topical therapy. The article reviews literature on topical treatments that have been assessed in clinical trials and real‐life studies lasting at least 12 months. Calcipotriol/bethamethasone dipropionate foam in maintenance treatment following the induction phase can improve efficacy and safety of topical therapy in psoriatic patients. Introduction of new topical nonsteroidal drugs and the wider use of proactive therapy seem to be crucial to achieve satisfactory long‐term outcomes in psoriasis.

show abstract

Section: Medications Used In Long-term Topical Therapy Of Psoriasismentioning

confidence: 92%

Section: Proactive Topical Therapymentioning

confidence: 99%

Section: Medications Used In Long-term Topical Therapy Of Psoriasismentioning

confidence: 99%

Section: Proactive Topical Therapymentioning

confidence: 99%

See 2 more Smart Citations

Proactive therapy: New perspectives for long‐term topical treatment of psoriasis

Lis‐Święty

Frątczak

2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“… 12 Finally, proactive management of plaque psoriasis with Cal/BD foam was more cost-effective compared with reactive management. 13 …”

Section: Introductionmentioning

confidence: 99%

Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports

Apalla¹,

Perrussel²,

Rallis³

2022

DIC

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease affecting about 100 million people worldwide. Around 80% of patients can be treated with topical agents, most commonly corticosteroids and vitamin D analogues. A topical foam formulation of calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (Cal/BD foam; Enstilar ® ) is approved for the daily treatment of psoriasis for up to 4 weeks and twice-weekly thereafter as maintenance treatment (after initial 4-week treatment success). Long-term proactive maintenance with Cal/BD foam for plaque psoriasis has been shown to prolong the time to first relapse, reduce the number of relapses and increase days in remission in the PSO-LONG trial. Four case studies of proactive management with Cal/BD foam for the treatment of plaque psoriasis for up to 12 months from initial presentation are described. These case studies provide real-world evidence on the long-term effectiveness of proactive management with Cal/BD foam as well as the improvement and maintenance of health-related quality of life. Cal/BD foam was well tolerated.

show abstract

Topical foam as a promising carrier system for active pharmaceutical ingredients: review of clinical studies

Kotwiski,

Albuquerque,

Lucchese

2023

Pharmaceutical Development and Technology

View full text Add to dashboard Cite

Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland

Cited by 3 publications

References 18 publications

Proactive therapy: New perspectives for long‐term topical treatment of psoriasis

Proactive therapy: New perspectives for long‐term topical treatment of psoriasis

Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports

Topical foam as a promising carrier system for active pharmaceutical ingredients: review of clinical studies

Contact Info

Product

Resources

About